Company intelligence / Profile preview

ONESTX

Seville, Andalusia, Spainonestx.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

ONESTX has demonstrated in animal models (C. elegans and mice) that increasing levels of certain neurosteroids via steroid sulfatase inhibition can improve memory and lifespan. In models of Alzheimer’s disease, this approach led to improvements in cognitive symptoms. The company’s programs are currently at the pre-clinical stage with promising results in both nematode and mammalian systems

Therapeutic areas: Neurology
Modalities: Small molecules (specifically steroid sulfatase inhibitors)
Industry: Biotech

Drug pipeline

1 asset

LON-22

Preclinical

Beyond the preview

Go deeper on ONESTX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONESTX.

Explore the full profile